Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50-Day Moving Average of $5.67

Capricor Therapeutics Inc (NASDAQ:CAPR) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.67 and traded as high as $6.75. Capricor Therapeutics shares last traded at $6.47, with a volume of 172,136 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. StockNews.com initiated coverage on shares of Capricor Therapeutics in a research report on Thursday, August 17th. They set a “sell” rating for the company. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, August 15th.

Capricor Therapeutics Stock Up 0.2 %

The firm has a market capitalization of $166.78 million, a P/E ratio of -5.53 and a beta of 3.88. The company’s 50 day moving average is $5.67 and its 200-day moving average is $4.86.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.05. Capricor Therapeutics had a negative net margin of 309.05% and a negative return on equity of 323.39%. The firm had revenue of $3.92 million for the quarter. On average, analysts predict that Capricor Therapeutics Inc will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CAPR. Tower Research Capital LLC TRC lifted its position in shares of Capricor Therapeutics by 138.7% during the first quarter. Tower Research Capital LLC TRC now owns 8,770 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 5,096 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Capricor Therapeutics during the third quarter valued at about $61,000. Charles Schwab Investment Management Inc. bought a new position in shares of Capricor Therapeutics during the first quarter valued at about $57,000. Virtu Financial LLC bought a new position in shares of Capricor Therapeutics during the first quarter valued at about $71,000. Finally, HighTower Advisors LLC lifted its position in shares of Capricor Therapeutics by 17.8% during the fourth quarter. HighTower Advisors LLC now owns 19,885 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 3,001 shares in the last quarter. 10.18% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.